Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Neural Regulation01:37

Neural Regulation

39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Striatal Tau Pathology Underlies Monoaminergic Disruption in Progressive Supranuclear Palsy.

Clinical nuclear medicine·2026
Same author

Regional wasteosome accumulation across neurodegenerative diseases points to a shared underlying mechanism potentially related to glymphatic insufficiency.

Acta neuropathologica communications·2026
Same author

Repeat expansions in Parkinson's disease and parkinsonism across ancestries: insights from a global genetic cohort.

medRxiv : the preprint server for health sciences·2026
Same author

Large-scale functional annotation establishes a reference framework for human <i>LRRK2</i> variants.

medRxiv : the preprint server for health sciences·2026
Same author

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Deciphering Freezing of Gait: What Neuropathology Reveals About an Episodic Phenomenon.

The European journal of neuroscience·2026
Same journal

Surgical Intervention for Posthyperglycemic Hemiballismus: Illustrative Case and Literature Review.

Movement disorders clinical practice·2026
Same journal

Cardiac Sympathetic Neuroimaging in Autonomic Synucleinopathies: <sup>123</sup>I-Metaiodobenzylguanidine and <sup>18</sup>F-Dopamine.

Movement disorders clinical practice·2026
Same journal

Acetazolamide-Responsive Exertion-Triggered Episodic Ataxia in DHDDS-Related Congenital Disorder of Glycosylation.

Movement disorders clinical practice·2026
Same journal

Epileptic-Dyskinetic Encephalopathy in Snijders Blok-Campeau Syndrome: Expanding the Phenotypic Spectrum.

Movement disorders clinical practice·2026
Same journal

Hardware Sophistications in Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease; Is the Juice Worth the Squeeze?

Movement disorders clinical practice·2026
Same journal

Correction to "Advancing Neuromodulation for Functional Movement Disorders: A Contemporary Narrative Review of Evidence, Gaps, and Future Outlook".

Movement disorders clinical practice·2026
See all related articles

Related Experiment Video

Updated: Sep 9, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.9K

Progressive Supranuclear Palsy-A Global Review.

Prashanth Lingappa Kukkle1, Rosy Neupane1, Alexandar Pantelyat2

  • 1Parkinson's Disease and Movement Disorders Clinic, Bangalore, India.

Movement Disorders Clinical Practice
|September 3, 2025
PubMed
Summary
This summary is machine-generated.

Progressive Supranuclear Palsy (PSP) shows significant global variation in prevalence and presentation. Addressing regional disparities in diagnosis and care is crucial for improving patient outcomes worldwide.

Keywords:
PSP study groupclinical profileglobal comparisonprogressive supranuclear palsy

More Related Videos

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.0K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.3K

Related Experiment Videos

Last Updated: Sep 9, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.9K
Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases
09:36

Human Neural Organoids for Studying Brain Cancer and Neurodegenerative Diseases

Published on: June 28, 2019

10.0K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.3K

Area of Science:

  • Neuroscience
  • Epidemiology
  • Genetics

Background:

  • Progressive Supranuclear Palsy (PSP) is a rare, severe neurodegenerative tauopathy with diverse clinical phenotypes.
  • Significant geographic variations exist in PSP prevalence, clinical presentations, and prognosis.

Purpose of the Study:

  • To systematically review global epidemiological variations, clinical phenotypes, diagnostic practices, and management strategies for PSP.
  • To identify regional disparities and influencing genetic and environmental factors in PSP.

Main Methods:

  • Comprehensive literature search following PRISMA guidelines.
  • Analysis of studies on PSP epidemiology, phenotypes, diagnosis, risk factors, treatments, and prognoses.
  • Data categorized by geography, considering regional variations.

Main Results:

  • Global PSP prevalence is 5-6.4 per 100,000, influenced by diagnostic criteria and healthcare infrastructure.
  • Common PSP symptoms include gaze palsy, falls, cognitive, and motor dysfunction.
  • Prognosis varies by subtype (e.g., PSP-RS 5-7 years, PSP-P 8-12 years); regional differences in genetics (MAPT H1 haplotype), environment, and healthcare access noted.

Conclusions:

  • Regional disparities in PSP prevalence, phenotypes, and healthcare access necessitate standardized diagnostic criteria.
  • Targeted genetic/environmental studies and equitable healthcare strategies are essential.
  • Enhanced global collaboration is vital for improving PSP diagnosis, management, and outcomes.